Revacept in Symptomatic Carotid Stenosis
Carotid StenosisAtherosclerosis4 morePatients suffering from symptomatic carotid artery stenosis, transient ischemic attacks (TIAs), amaurosis fugax or stroke receive either Revacept (single dose) plus antiplatelet monotherapy or monotherapy alone. Patients receive a single dose of trial medication by intravenous infusion for 20 minutes. Patients are followed up one and three days after treatment, at 3 months and by a telephone interview at 12 months.
Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy
Carotid Artery DiseaseStroke2 moreThe objective of the CANOPY trial is to assess the continued safety and effectiveness of the RX Acculink Carotid Stent System under commercial use in subjects at standard risk for adverse events from Carotid Endarterectomy (CEA) enrolled by physicians with a range of carotid stenting experience.
Ocular Manifestations in Rheumatic Diseases
UveitisConjunctivitis16 moreThis is a search strategy for determining the prevalence of ocular complications in inflammatory rheumatic diseases for the purposes of a meta analysis.